Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease

FB102 (10 mg/kg induction doses and 3 mg/kg or 5 mg/kg maintenance doses) or placebo arms in a 2:2:1 ratio.

Placebo